<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03127644</url>
  </required_header>
  <id_info>
    <org_study_id>D9482C00002</org_study_id>
    <nct_id>NCT03127644</nct_id>
  </id_info>
  <brief_title>ZS Ph2/3 Dose-response Study in Japan</brief_title>
  <official_title>A Phase 2/3 Multicenter, Dose-response Study to Assess Efficacy and Safety of ZS (Sodium Zirconium Cyclosilicate), in Japanese Patients With Hyperkalemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess efficacy of 5 g three times daily (TID) and 10 g TID ZS versus placebo in Japanese
      patients with hyperkalemia (serum potassium [S-K] ≥ 5.1 mmol/L and ≤ 6.5 mmol/L).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients not receiving any therapy for hyperkalemia and with 2 consecutive i-STAT potassium
      values of ≥ 5.1 mmol/L and ≤ 6.5 mmol/L will be enrolled and randomized 1:1:1 to receive ZS 5
      g, ZS 10 g, or placebo TID for 48 hours.

      Throughout the study most potassium values will be measured at fasting before taking study
      drug. Nothing should be taken by mouth except water, coffee or tea, with or without milk
      and/or sugar, and essential medications, prior to the blood collection for a minimum of 8
      hours. Potassium level should be determined by both i-STAT and the Central Laboratory on all
      occasions. Treatment decisions (eg, stopping rules) will be made based on i-STAT potassium
      values, as these provide clinical sites with a real-time measurement. Statistical analyses on
      the study data will in principle be based on S-K values as measured by the central
      laboratory.

      Safety and tolerability will be assessed on an ongoing basis. Standard study assessments
      including blood potassium, clinical chemistry (including calcium, magnesium, sodium,
      phosphate, creatinine, bicarbonate, and blood urea nitrogen [BUN]) and hematology parameters,
      urinalysis, vital signs, physical examinations, and electrocardiograms (ECGs) will be
      assessed during the study at the time points specified in the assessments schedule. All women
      of childbearing potential will have a urine pregnancy test prior to enrollment and at their
      End of Study (EOS) visit.

      Stopping rules will be implemented to ensure subjects discontinue the study treatment and
      receive alternative therapy in case of significant hyperkalemia, hypokalemia, or significant
      cardiac arrhythmias.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2017</start_date>
  <completion_date type="Actual">February 23, 2018</completion_date>
  <primary_completion_date type="Actual">February 23, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exponential rate of change in serum potassium (S-K) values</measure>
    <time_frame>Through 48-hour initial hours</time_frame>
    <description>Exponential rate of change in serum potassium (S-K) values during the initial 48 hours of study drug treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieved normokalemia</measure>
    <time_frame>Through 48-hour initial hours</time_frame>
    <description>Proportion of patients who achieved normokalemia at 48 hours after start of dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exponential rate of change in serum potassium (S-K) values</measure>
    <time_frame>Through 24-hour initial hours</time_frame>
    <description>Exponential rate of change in serum potassium (S-K) values during the initial 24 hours of study drug treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieved normokalemia</measure>
    <time_frame>Through 24-hour initial hours</time_frame>
    <description>Proportion of patients who achieved normokalemia at 24 hours after start of dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieved normokalemia</measure>
    <time_frame>Through 48-hour initial hours (Serum Potassium Collection Times Study Day 1: 0 hour (pre-dose), 1, 2, 4 hours post Dose 1, 90 minutes post Dose 2, Day 2: 0 hour (pre-dose), 1, 4 hours post Dose 1, Day 3: 0 hour)</time_frame>
    <description>Proportion of patients who achieved normokalemia at each scheduled potassium assessment time-point after start of dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in serum potassium (S-K) values</measure>
    <time_frame>Through 48-hour initial hours</time_frame>
    <description>Mean change from baseline in serum potassium (S-K) values at all measured time intervals post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to normalization in serum potassium (S-K) values</measure>
    <time_frame>Through 48-hour initial hours</time_frame>
    <description>Time to normalization in serum potassium (S-K) values (normalization defined as serum potassium (S-K) values between 3.5 and 5.0 mmol/L, inclusive)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in serum potassium (S-K) values</measure>
    <time_frame>Through 48-hour initial hours</time_frame>
    <description>Mean percent change from baseline in serum potassium (S-K) values at all measured time intervals post dose</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Hyperkalemia</condition>
  <arm_group>
    <arm_group_label>Sodium Zirconium Cyclosilicate (ZS) 5g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Suspension administered 5g orally three times daily for 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Zirconium Cyclosilicate (ZS) 10g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Suspension administered 10g orally three times daily for 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo suspension administered orally placebo three times daily for 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Zirconium Cyclosilicate (ZS) 5g</intervention_name>
    <description>Suspension administered 5g orally three times daily for 48 hours.</description>
    <arm_group_label>Sodium Zirconium Cyclosilicate (ZS) 5g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Zirconium Cyclosilicate (ZS) 10g</intervention_name>
    <description>Suspension administered 10g orally three times daily for 48 hours.</description>
    <arm_group_label>Sodium Zirconium Cyclosilicate (ZS) 10g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo suspension administered orally placebo three times daily for 48 hours.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures.

          -  Patients aged ≥18. For patients aged &lt;20 years, a written informed consent should be
             obtained from the patient and his or her legally acceptable representative.

          -  Two consecutive i-STAT potassium values, measured 60 (± 10) minutes apart, both values
             should be ≥ 5.1 mmol/L and ≤ 6.5 mmol/L and measured within 1 day before the first
             dose of study drug on Study Day 1.

          -  Ability to have repeated blood draws or effective venous catheterization.

          -  Female patients must be 1 year post-menopausal, surgically sterile, or using an
             acceptable method of contraception (an acceptable method of contraception is defined
             as a barrier method in conjunction with a spermicide) for the duration of the study
             (from the time they sign consent) and for 3 months after the last dose of ZS/matching
             placebo to prevent pregnancy. In addition, oral contraceptives, approved contraceptive
             implant, long-term injectable contraception, intrauterine device, or tubal ligation
             are allowed. Oral contraception alone is not acceptable; additional barrier methods in
             conjunction with spermicide must be used.

        Exclusion Criteria:

          -  Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
             staff and/or staff at the study site)

          -  Cause or symptoms of pseudohyperkalemia, such as

               1. hemolyzed blood specimen due to excessive fist clenching to make veins prominent

               2. hemolyzed blood specimen due to difficult or traumatic venepuncture

               3. history of severe leukocytosis or thrombocytosis

          -  Patients treated with lactulose, rifaximin, or other non-absorbed antibiotics for
             hyperammonemia within 7 days prior to first dose of study drug on Study Day 1

          -  Patients treated with resins (such as sevelamer hydrochloride, sodium polystyrene
             sulfonate [SPS; e.g. Kayexalate®] or calcium polystyrene sulfonate [CPS]), calcium
             acetate, calcium carbonate, or lanthanum carbonate, within 7 days prior to the first
             dose of study drug

          -  Patients with a life expectancy of less than 3 months

          -  Patients who are severely physically or mentally incapacitated and who, in the opinion
             of investigator, are unable to perform the patients' tasks associated with the
             protocol

          -  Female patients who are pregnant, lactating, or planning to become pregnant

          -  Patients who have an active or history of diabetic ketoacidosis

          -  Presence of any condition which, in the opinion of the investigator, places the
             patient at undue risk or potentially jeopardizes the quality of the data to be
             generated

          -  Known hypersensitivity or previous anaphylaxis to ZS or to components thereof

          -  Treatment with a drug or device within the last 30 days that has not received
             regulatory approval at the time of study entry

          -  Patients with cardiac arrhythmias that require immediate treatment

          -  Patients on dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiba-shi</city>
        <zip>260-8712</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiba-shi</city>
        <zip>263-0043</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanyu-shi</city>
        <zip>348-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Higashiibaraki-gun</city>
        <zip>311-3193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hitachinaka-shi</city>
        <zip>312-0057</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ina-shi</city>
        <zip>396-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kagoshima-shi</city>
        <zip>892-8580</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kahoku-gun</city>
        <zip>920-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kamakura-shi</city>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kanazawa-shi</city>
        <zip>920-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kasugai-shi</city>
        <zip>486-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kawachinagano-shi</city>
        <zip>586-8521</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kawasaki-shi</city>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kitakyushu-shi</city>
        <zip>802-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koga-shi</city>
        <zip>306-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kusatsu-shi</city>
        <zip>525-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsudo-shi</city>
        <zip>271-0077</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsuyama-shi</city>
        <zip>791-8026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <zip>457-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Naka-shi</city>
        <zip>311-0113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omura-shi</city>
        <zip>856-8562</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shimajiri-gun</city>
        <zip>901-0493</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shizuoka-shi</city>
        <zip>421-0117</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yao-shi</city>
        <zip>581-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yotsukaido-shi</city>
        <zip>284-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkalemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

